Cancer Network
August 08, 2023
A Cancer Network article on FDA approval for a therascreen platelet-derived growth factor receptor alpha PCR kit as a companion diagnostic for identifying patients with gastrointestinal stromal tumors (GIST) includes an older quote from Michael Heinrich, M.D., on the FDA approval of avaprinitib. He said: “Today's approval of [avapritinib] brings forward a new standard of care for patients with PDGFRA exon 18 mutant GIST, a genomically defined population that previously had very limited treatment options.”